A registered study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase not reported
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
- Evidence population
- Human clinical study registration
- Participants
- 74
- Population
- ALL · 65 Years to 80 Years
- Duration
- 2025-12-01 to 2026-12-01
- Intervention
- Vitamin D3 supplement; Protein-enriched biscuits; Control biscuit; Placebo oil
- Comparator
- Control Biscuit + Placebo Oil
- Outcomes measured
- Change in Appendicular Skeletal Muscle Index (ASMI) — Screening, baseline, week 6 and week 12 (end of the treatment); Muscle strenght — Screening, baseline, week 6 and week 12 (end of the treatment); Physical performance (SPPB score) — Screening, baseline, week 6 and week 12 (end of the treatment); C-Reactive protein (CRP) — Baseline, week 6 and week 12 (end of the treatment); Gut micorbiome modulation and metabolites — Baseline at at week 12 (end of the treatment); Nutritional intake — Baseline, week 6 and week 12 (end of the treatment); Nutritional habits — Enrollment; Quality of life of sarcopenic patients — Baseline, week 6 and week 12 (end of the treatment); Mini Nutritional Assessment (MNA®) — At the screening; Mini Mental State Examination (MMSE) — At the screening; Body mass index (BMI) — screening, baseline, week 6, week 12 (end of the treatment); Interleukin-6 (IL-6) — baseline, week 6, week 12 (end of the treatment); Tumor Necrosis Factor-alpha (TNF-α) — baseline, week 6, week 12 (end of the treatment); Leptin — baseline, week 6, week 12 (end of the treatment); IGF-1 — Baseline, week 6, week 12 (end of the treatment); Albumin — baseline, week 6, week 12 (end of the treatment); Oxidized LDL (oxLDL) — baseline, week 6 and week 12 (end of the treatment); 25OH-D (Total 25-OH Vitamin D) — baseline, week 6, week 12 (end of the treatment); Human Agrin (C-terminal fragment) — baseline, week 6, week 12 (end of the treatment); Triglyceride (TG) — baseline, week 6, week 12 (end of the treatment)
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Sarcopenia · 100%Title contains controlled term: sarcopenia. Abstract contains controlled term: sarcopenia. Source terminology contains: sarcopenia. Title supplies longevity context: elderly. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.